Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 98 entries
Sorted by: Best Match Show Resources per page
A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine.

Pharmaceutics

Kanacher T, Lindauer A, Mezzalana E, Michon I, Veau C, Mantilla JDG, Nock V, Fleury A.
PMID: 33302490
Pharmaceutics. 2020 Dec 08;12(12). doi: 10.3390/pharmaceutics12121191.

Physiologically-based pharmacokinetic (PBPK) modeling is a well-recognized method for quantitatively predicting the effect of intrinsic/extrinsic factors on drug exposure. However, there are only few verified, freely accessible, modifiable, and comprehensive drug-drug interaction (DDI) PBPK models. We developed a qualified...

Cite
Kanacher T, Lindauer A, Mezzalana E, et al. A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine. Pharmaceutics. 2020;12(12)doi: 10.3390/pharmaceutics12121191.
Kanacher, T., Lindauer, A., Mezzalana, E., Michon, I., Veau, C., Mantilla, J. D. G., Nock, V., & Fleury, A. (2020). A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine. Pharmaceutics, 12(12), . https://doi.org/10.3390/pharmaceutics12121191
Kanacher, Tobias, et al. "A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine." Pharmaceutics vol. 12,12 (2020). doi: https://doi.org/10.3390/pharmaceutics12121191
Kanacher T, Lindauer A, Mezzalana E, Michon I, Veau C, Mantilla JDG, Nock V, Fleury A. A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine. Pharmaceutics. 2020 Dec 08;12(12). doi: 10.3390/pharmaceutics12121191. PMID: 33302490; PMCID: PMC7764797.
Copy Download .nbib Format: NLM
Human iPSC-derived cardiomyocytes and pyridyl-phenyl mexiletine analogs.

Bioorganic & medicinal chemistry letters

Johnson M, Gomez-Galeno J, Ryan D, Okolotowicz K, McKeithan WL, Sampson KJ, Kass RS, Mercola M, Cashman JR.
PMID: 34062251
Bioorg Med Chem Lett. 2021 Aug 15;46:128162. doi: 10.1016/j.bmcl.2021.128162. Epub 2021 May 29.

In the United States, approximately one million individuals are hospitalized every year for arrhythmias, making arrhythmias one of the top causes of healthcare expenditures. Mexiletine is currently used as an antiarrhythmic drug but has limitations. The purpose of this...

Cite
Johnson M, Gomez-Galeno J, Ryan D, et al. Human iPSC-derived cardiomyocytes and pyridyl-phenyl mexiletine analogs. Bioorg Med Chem Lett. 2021;46:128162doi: 10.1016/j.bmcl.2021.128162.
Johnson, M., Gomez-Galeno, J., Ryan, D., Okolotowicz, K., McKeithan, W. L., Sampson, K. J., Kass, R. S., Mercola, M., & Cashman, J. R. (2021). Human iPSC-derived cardiomyocytes and pyridyl-phenyl mexiletine analogs. Bioorganic & medicinal chemistry letters, 46128162. https://doi.org/10.1016/j.bmcl.2021.128162
Johnson, Mark, et al. "Human iPSC-derived cardiomyocytes and pyridyl-phenyl mexiletine analogs." Bioorganic & medicinal chemistry letters vol. 46 (2021): 128162. doi: https://doi.org/10.1016/j.bmcl.2021.128162
Johnson M, Gomez-Galeno J, Ryan D, Okolotowicz K, McKeithan WL, Sampson KJ, Kass RS, Mercola M, Cashman JR. Human iPSC-derived cardiomyocytes and pyridyl-phenyl mexiletine analogs. Bioorg Med Chem Lett. 2021 Aug 15;46:128162. doi: 10.1016/j.bmcl.2021.128162. Epub 2021 May 29. PMID: 34062251.
Copy Download .nbib Format: NLM
Shock From Twisting Peaks: A Rare Case of Recurrent Torsades de Pointes Secondary to Leuprolide-Induced Prolonged QT.

Cureus

Abbasi D, Faiek S, Shetty S, Khan E.
PMID: 32782861
Cureus. 2020 Jul 07;12(7):e9041. doi: 10.7759/cureus.9041.

Leuprolide acetate is a synthetic nonpeptide analog that is a potent gonadotropin-releasing hormone receptor agonist. It is used in diverse clinical applications, including treatment for prostate cancer, endometriosis, and uterine fibroids as well as the in vitro fertilization technique....

Cite
Abbasi D, Faiek S, Shetty S, et al. Shock From Twisting Peaks: A Rare Case of Recurrent Torsades de Pointes Secondary to Leuprolide-Induced Prolonged QT. Cureus. 2020;12(7):e9041doi: 10.7759/cureus.9041.
Abbasi, D., Faiek, S., Shetty, S., & Khan, E. (2020). Shock From Twisting Peaks: A Rare Case of Recurrent Torsades de Pointes Secondary to Leuprolide-Induced Prolonged QT. Cureus, 12(7), e9041. https://doi.org/10.7759/cureus.9041
Abbasi, Danish, et al. "Shock From Twisting Peaks: A Rare Case of Recurrent Torsades de Pointes Secondary to Leuprolide-Induced Prolonged QT." Cureus vol. 12,7 (2020): e9041. doi: https://doi.org/10.7759/cureus.9041
Abbasi D, Faiek S, Shetty S, Khan E. Shock From Twisting Peaks: A Rare Case of Recurrent Torsades de Pointes Secondary to Leuprolide-Induced Prolonged QT. Cureus. 2020 Jul 07;12(7):e9041. doi: 10.7759/cureus.9041. PMID: 32782861; PMCID: PMC7410506.
Copy Download .nbib Format: NLM
Sympathectomy via a posterior approach after a failed trans-thoracic approach: a case of its use for arrhythmia.

Journal of neurosurgery. Pediatrics

Blatt D, Cheaney B, Holste K, Balaji S, Raslan AM.
PMID: 31923890
J Neurosurg Pediatr. 2020 Jan 10;1-6. doi: 10.3171/2019.11.PEDS19424. Epub 2020 Jan 10.

OBJECTIVE: Congenital long QT syndrome (LQTS) provides an opportunity for neurosurgical intervention. Medication and implantable cardiac defibrillator (ICD)-refractory patients often require left cardiac sympathetic denervation (LCSD) via anterior video-assisted thoracoscopic surgery (VATS). However, this approach has major pulmonary contraindications...

Cite
Blatt D, Cheaney B, Holste K, et al. Sympathectomy via a posterior approach after a failed trans-thoracic approach: a case of its use for arrhythmia. J Neurosurg Pediatr. 2020;1-6doi: 10.3171/2019.11.PEDS19424.
Blatt, D., Cheaney, B., Holste, K., Balaji, S., & Raslan, A. M. (2020). Sympathectomy via a posterior approach after a failed trans-thoracic approach: a case of its use for arrhythmia. Journal of neurosurgery. Pediatrics, 1-6. https://doi.org/10.3171/2019.11.PEDS19424
Blatt, Daniel, et al. "Sympathectomy via a posterior approach after a failed trans-thoracic approach: a case of its use for arrhythmia." Journal of neurosurgery. Pediatrics vol. (2020): 1-6. doi: https://doi.org/10.3171/2019.11.PEDS19424
Blatt D, Cheaney B, Holste K, Balaji S, Raslan AM. Sympathectomy via a posterior approach after a failed trans-thoracic approach: a case of its use for arrhythmia. J Neurosurg Pediatr. 2020 Jan 10;1-6. doi: 10.3171/2019.11.PEDS19424. Epub 2020 Jan 10. PMID: 31923890.
Copy Download .nbib Format: NLM
Illustrative and historic cases of phenoconversion.

American journal of translational research

Michaud V, Dow P, Turgeon J.
PMID: 35035679
Am J Transl Res. 2021 Dec 15;13(12):13328-13335. eCollection 2021.

Intersubject variability in drug response, whether related to efficacy or toxicity, is well recognized clinically. Over the years, drug selection from our pharmacologic armamentarium has moved from providers' preferred choices to more personalized treatments as clinicians' decisions are guided...

Cite
Michaud V, Dow P, Turgeon J. Illustrative and historic cases of phenoconversion. Am J Transl Res. 2021;13(12):13328-13335
Michaud, V., Dow, P., & Turgeon, J. (2021). Illustrative and historic cases of phenoconversion. American journal of translational research, 13(12), 13328-13335.
Michaud, Veronique, et al. "Illustrative and historic cases of phenoconversion." American journal of translational research vol. 13,12 (2021): 13328-13335.
Michaud V, Dow P, Turgeon J. Illustrative and historic cases of phenoconversion. Am J Transl Res. 2021 Dec 15;13(12):13328-13335. eCollection 2021. PMID: 35035679; PMCID: PMC8748136.
Copy Download .nbib Format: NLM
Cardiac Dysrhythmia Associated With Opioid Toxicity.

Cureus

Rawala MS, Gulati R, Rizvi S.
PMID: 32467816
Cureus. 2020 May 22;12(5):e8243. doi: 10.7759/cureus.8243.

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder involving abnormal motility. The patients are commonly started on symptom control management for IBS - diarrhea subtype by prescribing antimotility agents, usually having opioid agonist activity, and newer medications have...

Cite
Rawala MS, Gulati R, Rizvi S. Cardiac Dysrhythmia Associated With Opioid Toxicity. Cureus. 2020;12(5):e8243doi: 10.7759/cureus.8243.
Rawala, M. S., Gulati, R., & Rizvi, S. (2020). Cardiac Dysrhythmia Associated With Opioid Toxicity. Cureus, 12(5), e8243. https://doi.org/10.7759/cureus.8243
Rawala, Muhammad Shabbir, et al. "Cardiac Dysrhythmia Associated With Opioid Toxicity." Cureus vol. 12,5 (2020): e8243. doi: https://doi.org/10.7759/cureus.8243
Rawala MS, Gulati R, Rizvi S. Cardiac Dysrhythmia Associated With Opioid Toxicity. Cureus. 2020 May 22;12(5):e8243. doi: 10.7759/cureus.8243. PMID: 32467816; PMCID: PMC7249760.
Copy Download .nbib Format: NLM
Drug Repurposing for Rare Diseases: A Role for Academia.

Frontiers in pharmacology

van den Berg S, de Visser S, Leufkens HGM, Hollak CEM.
PMID: 34744726
Front Pharmacol. 2021 Oct 20;12:746987. doi: 10.3389/fphar.2021.746987. eCollection 2021.

No abstract available.

Cite
van den Berg S, de Visser S, Leufkens HGM, et al. Drug Repurposing for Rare Diseases: A Role for Academia. Front Pharmacol. 2021;12:746987doi: 10.3389/fphar.2021.746987.
van den Berg, S., de Visser, S., Leufkens, H. G. M., & Hollak, C. E. M. (2021). Drug Repurposing for Rare Diseases: A Role for Academia. Frontiers in pharmacology, 12746987. https://doi.org/10.3389/fphar.2021.746987
van den Berg, Sibren, et al. "Drug Repurposing for Rare Diseases: A Role for Academia." Frontiers in pharmacology vol. 12 (2021): 746987. doi: https://doi.org/10.3389/fphar.2021.746987
van den Berg S, de Visser S, Leufkens HGM, Hollak CEM. Drug Repurposing for Rare Diseases: A Role for Academia. Front Pharmacol. 2021 Oct 20;12:746987. doi: 10.3389/fphar.2021.746987. eCollection 2021. PMID: 34744726; PMCID: PMC8564285.
Copy Download .nbib Format: NLM
Mexiletine and False Positive Urine Drug Screen for Amphetamine: A Case Review.

Case reports in medicine

Sohal S, Sous M, Pethe G, Padmanabhan SV, Akbari R, Dadkhah S.
PMID: 34887926
Case Rep Med. 2021 Nov 30;2021:7134394. doi: 10.1155/2021/7134394. eCollection 2021.

Advanced heart failure patients commonly suffer from ventricular arrhythmias which can be managed by antiarrhythmic drugs like mexiletine. These ventricular arrhythmias can be complicated by illicit drug use which alter outcomes and can potentially impact the patient-physician relationship through...

Cite
Sohal S, Sous M, Pethe G, et al. Mexiletine and False Positive Urine Drug Screen for Amphetamine: A Case Review. Case Rep Med. 2021;2021:7134394doi: 10.1155/2021/7134394.
Sohal, S., Sous, M., Pethe, G., Padmanabhan, S. V., Akbari, R., & Dadkhah, S. (2021). Mexiletine and False Positive Urine Drug Screen for Amphetamine: A Case Review. Case reports in medicine, 20217134394. https://doi.org/10.1155/2021/7134394
Sohal, Sumit, et al. "Mexiletine and False Positive Urine Drug Screen for Amphetamine: A Case Review." Case reports in medicine vol. 2021 (2021): 7134394. doi: https://doi.org/10.1155/2021/7134394
Sohal S, Sous M, Pethe G, Padmanabhan SV, Akbari R, Dadkhah S. Mexiletine and False Positive Urine Drug Screen for Amphetamine: A Case Review. Case Rep Med. 2021 Nov 30;2021:7134394. doi: 10.1155/2021/7134394. eCollection 2021. PMID: 34887926; PMCID: PMC8651372.
Copy Download .nbib Format: NLM
Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine.

Case reports in cardiology

O'Laughlin JP, Mehta PH, Wong BC.
PMID: 27478650
Case Rep Cardiol. 2016;2016:4626279. doi: 10.1155/2016/4626279. Epub 2016 Jul 12.

We present a case of a syncopal episode resulting from significant QT interval prolongation in a patient on hydroxychloroquine for the treatment of systemic lupus erythematosus and end stage renal disease. The patient had been treated with hydroxychloroquine for...

Cite
O'Laughlin JP, Mehta PH, Wong BC. Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine. Case Rep Cardiol. 2016;2016:4626279doi: 10.1155/2016/4626279.
O'Laughlin, J. P., Mehta, P. H., & Wong, B. C. (2016). Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine. Case reports in cardiology, 20164626279. https://doi.org/10.1155/2016/4626279
O'Laughlin, John P, et al. "Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine." Case reports in cardiology vol. 2016 (2016): 4626279. doi: https://doi.org/10.1155/2016/4626279
O'Laughlin JP, Mehta PH, Wong BC. Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine. Case Rep Cardiol. 2016;2016:4626279. doi: 10.1155/2016/4626279. Epub 2016 Jul 12. PMID: 27478650; PMCID: PMC4960328.
Copy Download .nbib Format: NLM
Mexiletine infusion challenge test for neonatal long QT syndrome with 2:1 atrioventricular block.

Journal of arrhythmia

Okuwaki H, Kato Y, Lin L, Nozaki Y, Takahashi-Igari M, Horigome H.
PMID: 31410243
J Arrhythm. 2019 Jun 17;35(4):685-688. doi: 10.1002/joa3.12209. eCollection 2019 Aug.

For applying a genotype-based treatment in neonatal long QT syndrome (LQTS), early detection of the genotype becomes an important issue. We report a case of a neonate with LQTS type 3 that presented with 2:1 atrioventricular block and underwent...

Cite
Okuwaki H, Kato Y, Lin L, et al. Mexiletine infusion challenge test for neonatal long QT syndrome with 2:1 atrioventricular block. J Arrhythm. 2019;35(4):685-688doi: 10.1002/joa3.12209.
Okuwaki, H., Kato, Y., Lin, L., Nozaki, Y., Takahashi-Igari, M., & Horigome, H. (2019). Mexiletine infusion challenge test for neonatal long QT syndrome with 2:1 atrioventricular block. Journal of arrhythmia, 35(4), 685-688. https://doi.org/10.1002/joa3.12209
Okuwaki, Hajime, et al. "Mexiletine infusion challenge test for neonatal long QT syndrome with 2:1 atrioventricular block." Journal of arrhythmia vol. 35,4 (2019): 685-688. doi: https://doi.org/10.1002/joa3.12209
Okuwaki H, Kato Y, Lin L, Nozaki Y, Takahashi-Igari M, Horigome H. Mexiletine infusion challenge test for neonatal long QT syndrome with 2:1 atrioventricular block. J Arrhythm. 2019 Jun 17;35(4):685-688. doi: 10.1002/joa3.12209. eCollection 2019 Aug. PMID: 31410243; PMCID: PMC6686300.
Copy Download .nbib Format: NLM
Myotonic dystrophy type 1 drug development: A pipeline toward the market.

Drug discovery today

Pascual-Gilabert M, López-Castel A, Artero R.
PMID: 33798646
Drug Discov Today. 2021 Jul;26(7):1765-1772. doi: 10.1016/j.drudis.2021.03.024. Epub 2021 Mar 31.

Myotonic dystrophy type 1 (DM1) is a multisystemic neuromuscular genetic disease with an estimated prevalence of approximately at least half a million individuals based on its vast ethnic variation. Building upon a well-known physiopathology and several proof-of-concept therapeutic approaches,...

Cite
Pascual-Gilabert M, López-Castel A, Artero R. Myotonic dystrophy type 1 drug development: A pipeline toward the market. Drug Discov Today. 2021;26(7):1765-1772doi: 10.1016/j.drudis.2021.03.024.
Pascual-Gilabert, M., López-Castel, A., & Artero, R. (2021). Myotonic dystrophy type 1 drug development: A pipeline toward the market. Drug discovery today, 26(7), 1765-1772. https://doi.org/10.1016/j.drudis.2021.03.024
Pascual-Gilabert, Marta, et al. "Myotonic dystrophy type 1 drug development: A pipeline toward the market." Drug discovery today vol. 26,7 (2021): 1765-1772. doi: https://doi.org/10.1016/j.drudis.2021.03.024
Pascual-Gilabert M, López-Castel A, Artero R. Myotonic dystrophy type 1 drug development: A pipeline toward the market. Drug Discov Today. 2021 Jul;26(7):1765-1772. doi: 10.1016/j.drudis.2021.03.024. Epub 2021 Mar 31. PMID: 33798646; PMCID: PMC8372527.
Copy Download .nbib Format: NLM
Quality of meta-analyses of non-opioid, pharmacological, perioperative interventions for chronic postsurgical pain: a systematic review.

Regional anesthesia and pain medicine

McGregor RH, Warner FM, Linde LD, Cragg JJ, Osborn JA, Varshney VP, Schwarz SKW, Kramer JLK.
PMID: 35027479
Reg Anesth Pain Med. 2022 Jan 13; doi: 10.1136/rapm-2021-102981. Epub 2022 Jan 13.

BACKGROUND: In an attempt to aggregate observations from clinical trials, several meta-analyses have been published examining the effectiveness of systemic, non-opioid, pharmacological interventions to reduce the incidence of chronic postsurgical pain.OBJECTIVE: To inform the design and reporting of future...

Cite
McGregor RH, Warner FM, Linde LD, et al. Quality of meta-analyses of non-opioid, pharmacological, perioperative interventions for chronic postsurgical pain: a systematic review. Reg Anesth Pain Med. 2022;doi: 10.1136/rapm-2021-102981.
McGregor, R. H., Warner, F. M., Linde, L. D., Cragg, J. J., Osborn, J. A., Varshney, V. P., Schwarz, S. K. W., & Kramer, J. L. K. (2022). Quality of meta-analyses of non-opioid, pharmacological, perioperative interventions for chronic postsurgical pain: a systematic review. Regional anesthesia and pain medicine, . https://doi.org/10.1136/rapm-2021-102981
McGregor, Rachel H, et al. "Quality of meta-analyses of non-opioid, pharmacological, perioperative interventions for chronic postsurgical pain: a systematic review." Regional anesthesia and pain medicine vol. (2022). doi: https://doi.org/10.1136/rapm-2021-102981
McGregor RH, Warner FM, Linde LD, Cragg JJ, Osborn JA, Varshney VP, Schwarz SKW, Kramer JLK. Quality of meta-analyses of non-opioid, pharmacological, perioperative interventions for chronic postsurgical pain: a systematic review. Reg Anesth Pain Med. 2022 Jan 13; doi: 10.1136/rapm-2021-102981. Epub 2022 Jan 13. PMID: 35027479.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 98 entries